53766-80-6

Usage

Uses

Used in Antiviral Applications:
2',3'-Didehydro-2',3'-dideoxyguanosine is used as an antiviral agent for the treatment of various viral infections, particularly HIV and hepatitis B virus. It modulates the process of viral replication by inhibiting the activity of the viral enzyme reverse transcriptase, effectively reducing viral load and improving clinical outcomes in patients.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2',3'-Didehydro-2',3'-dideoxyguanosine is used as a key component in the development of new antiviral drugs. Its unique structure and broad-spectrum antiviral activity make it a promising candidate for the creation of innovative therapeutic agents to combat viral infections.
Used in Clinical Trials:
2',3'-Didehydro-2',3'-dideoxyguanosine is used as a subject of clinical trials to evaluate its safety, efficacy, and potential as a treatment for viral infections. These trials aim to determine the optimal dosage, administration methods, and potential side effects of DHPG, as well as its synergistic effects when combined with other antiviral drugs.

InChI:InChI=1/C10H11N5O3/c11-10-13-8-7(9(17)14-10)12-4-15(8)6-2-1-5(3-16)18-6/h1-2,4-6,16H,3H2,(H3,11,13,14,17)/t5-,6+/m0/s1

Upstream product

• 115913-86-5 6-O-<(p-nitrophenyl)ethyl>-3'-O-mesyl-2'-deoxyguanosine 
• 64350-24-9 N²-isobutyryl-2'-deoxyguanosine 
• 119794-50-2 5'-O-(tert-butyldimethylsilyl)-N²-isobutyryl-2',3'-bis-O-<(methylthio)thiocarbonyl>guanosine 
• 119794-37-5 5'-O-(tert-butyldimethylsilyl)-N²-isobutyryl-2',3'-bis-O-<<(β-cyanoethyl)thio>thiocarbonyl>guanosine 
• 118-00-3 G 
• 119794-39-7 5'-O-(tert-butyldimethylsilyl)-N²-isobutyryl-2',3'-didehydro-2',3'-dideoxyguanosine 
• 84870-95-1 N²,5'-O-bis(monomethoxytrityl)-2'-deoxyguanosine 
• 961-07-9 2'-Deoxyguanosine 
• 119794-40-0 N²-isobutyryl-2',3'-didehydro-2',3'-dideoxyguanosine 
• 119794-38-6 5'-O-(tert-butyldimethylsilyl)-N²-isobutyryl-2',3'-O-thionocarbonylguanosine 
• 89494-39-3 5'-O-(tert-butyldimethylsilyl)-N²-isobutyrylguanosine 

Downstream Products

• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 

Relevant academic research and scientific papers

Molybdopterin biosynthesis: Trapping an unusual purine ribose adduct in the MoaA-catalyzed reaction

MoaA/MoaC catalyze a remarkable rearrangement reaction in which guanosine-5′-triphosphate (GTP) is converted to cyclic pyranopterin monophosphate (cPMP). In this reaction, the C8 of GTP is inserted between the C2′ and the C3′ carbons of the GTP ribose. Previous experiments with GTP isotopomers demonstrated that the ribose C3′ hydrogen atom is abstracted by the adenosyl radical. This led to a novel mechanistic proposal involving an intermediate with a bond between the C8 of guanine and C3′ of the ribose. This paper describes the use of 2′,3′-dideoxyGTP to trap this intermediate.

Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides

A series of base-modified pyrimidine 3'-azido-2',3'-dideoxynucleosides and 3'-substituted purine and pyrimidine 2',3'-dideoxynucleosides have been synthesized and evaluated for their inhibitory activity against human immunodeficiency virus (HIV) replication in MT-4 cells. The following pyrimidine derivatives emerged as the most potent and/or selective inhibitors of HIV-induced cytopathogenicity (in order of decreasing selectivity: 3'-azido-3'-deoxythymidine (AZT), 3'-azido-2',3'-dideoxyuridine (AzddUrd), 3'-azido-2',3'-dideoxy-5-methylcytidine (AzddMeCyd), 3'-fluoro-ddUrd (FddUrd), 3'-fluoro-ddThd (FddThd), the N4-hydroxylated derivative of AzddMeCyd and the N4-methylated derivative of AzddMeCyd. Among the purine 2',3'-dideoxynucleosides, 3'-azido-2',3'-dideoxyguanosine (AzddGuo), 3'-fluoro-ddGuo (FddGuo), and 3'-fluoro-2,6-diaminopurine 2',3'-dideoxynucleoside (FddDAPR) were the most selective inhibitors of HIV replication.